Endre Kjarland
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Endre Kjarland has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Bjørn Tore Gjertsen
Haukeland University Hospital Bergen Norway
1 shared publication - Frederic Pendino
Department of Molecular Biology, University of Bergen, Bergen, Norway
1 shared publication - Johan Richard Lillehaug
Department of Molecular Biology, University of Bergen, Bergen, Norway
1 shared publication - Line M. Myklebust
Department of Molecular Biology, University of Bergen, HIB, Thormoehlens gt. 55, N-5020, Bergen, Norway
1 shared publication R. Kleppe
1 shared publication- Stein Ove Døskeland
The Department of Biomedicine, University of Bergen, 5009 Bergen, Norway
1 shared publication
Latest Publications
- Open Access
- 23 April 2007
- Published by Springer Nature in Molecular Cancer
- Vol. 6 (1) , 31
LEDGF/p75 has increased expression in blasts from chemotherapy-resistant human acute myelogenic leukemia patients and protects leukemia cells from apoptosis in vitro
Background: Relapse due to chemoresistant residual disease is a major cause of death in acute myelogenous leukemia (AML). The present study was undertaken to elucidate the molecular mechanisms of chemoresistance by comparing differential gene expression in blasts from patients with resistant relapsing AML and chemosensitive AML.Results: About 20 genes were identified as preferentially expressed in blasts pooled from patients with resistant disease, as compared to chemosensitive AML blasts, based on differential gene expression screening. Half of these genes encoded proteins related to protein translation, of these a novel protein related to the ribosomal stalk protein P0. Other upregulated mRNAs coded for cytochrome C oxidase III, the transcription factors ERF-2/TIS11d, and the p75 and p52 splice variants of Lens Epithelial Derived Growth Factor (LEDGF). Analysis of blasts from single patients disclosed that LEDGF/p75 was the most consistently upregulated mRNA in resistant AML. Transfection experiments demonstrated that LEDGF/p75 and p52b antagonized daunorubicin-induced and cAMP-induced apoptosis in an AML cell line. Also HEK-293 cells were protected against daunorubicin by LEDGF/p75 and p52b, whereas LEDGF/p52 splice variants lacking exon 6 had proapoptotic effects. Interestingly, full length LEDGF/p75 protected against truncated pro-apoptotic LEDGF/p75.Conclusion: Our results provide evidence for an association between the overexpression of genes encoding survival proteins like LEDGF/p75 and chemo-resistance in acute myelogenous leukemia. LEDGF/p75 has previously not been shown to protect against chemotherapy, and is a potential drug target in AML.
- 23 April 2007
- Published by Springer Nature in Molecular Cancer
- Vol. 6 (1) , 31
Open AccessLEDGF/p75 has increased expression in blasts from chemotherapy-resistant human acute myelogenic leukemia patients and protects leukemia cells from apoptosis in vitro
Background: Relapse due to chemoresistant residual disease is a major cause of death in acute myelogenous leukemia (AML). The present study was undertaken to elucidate the molecular mechanisms of chemoresistance by comparing differential gene expression in blasts from patients with resistant relapsing AML and chemosensitive AML.Results: About 20 genes were identified as preferentially expressed in blasts pooled from patients with resistant disease, as compared to chemosensitive AML blasts, based on differential gene expression screening. Half of these genes encoded proteins related to protein translation, of these a novel protein related to the ribosomal stalk protein P0. Other upregulated mRNAs coded for cytochrome C oxidase III, the transcription factors ERF-2/TIS11d, and the p75 and p52 splice variants of Lens Epithelial Derived Growth Factor (LEDGF). Analysis of blasts from single patients disclosed that LEDGF/p75 was the most consistently upregulated mRNA in resistant AML. Transfection experiments demonstrated that LEDGF/p75 and p52b antagonized daunorubicin-induced and cAMP-induced apoptosis in an AML cell line. Also HEK-293 cells were protected against daunorubicin by LEDGF/p75 and p52b, whereas LEDGF/p52 splice variants lacking exon 6 had proapoptotic effects. Interestingly, full length LEDGF/p75 protected against truncated pro-apoptotic LEDGF/p75.Conclusion: Our results provide evidence for an association between the overexpression of genes encoding survival proteins like LEDGF/p75 and chemo-resistance in acute myelogenous leukemia. LEDGF/p75 has previously not been shown to protect against chemotherapy, and is a potential drug target in AML.
- 1 June 2006
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Biotechnology
- Vol. 7 (3) , 217-223
Does Isoform Diversity Explain Functional Differences in the 14-3-3Protein Family?
The 14-3-3 family of proteins was originally identified in 1967 as simply an abundant brain protein. However ittook almost 25 years before the ubiquitous role of 14-3-3 in cell biology was recognized when it was found to interactwith several signalling and proto-oncogene proteins. Subsequently 14-3-3 proteins were the first protein recognized tobind a discrete phosphoserine/threonine-binding motifs. In mammals the 14-3-3 protein family is comprised of seven ho-mologous isoforms. The 14-3-3 family members are expressed in all eukaryotes and although no single conserved func-tion of the 14-3-3s is apparent, their ability to bind other proteins seems a crucial characteristic. To date more than 300binding partners have been identified, of which most are phosphoproteins. Consequently, it has become clear that 14-3-3proteins are involved in the regulation of most cellular processes, including several metabolic pathways, redox-regulation,transcription, RNA processing, protein synthesis, protein folding and degradation, cell cycle, cytoskeletal organization andcellular trafficking. In this review we include recent reports on the regulation of 14-3-3 by phosphorylation, and discussthe possible functional significance of the existence of distinct 14-3-3 isoforms in light of recent proteomics studies. Inaddition we discuss 14-3-3 interaction as a possible drug target.
- 1 June 2006
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Biotechnology
- Vol. 7 (3) , 217-223
Does Isoform Diversity Explain Functional Differences in the 14-3-3Protein Family?
The 14-3-3 family of proteins was originally identified in 1967 as simply an abundant brain protein. However ittook almost 25 years before the ubiquitous role of 14-3-3 in cell biology was recognized when it was found to interactwith several signalling and proto-oncogene proteins. Subsequently 14-3-3 proteins were the first protein recognized tobind a discrete phosphoserine/threonine-binding motifs. In mammals the 14-3-3 protein family is comprised of seven ho-mologous isoforms. The 14-3-3 family members are expressed in all eukaryotes and although no single conserved func-tion of the 14-3-3s is apparent, their ability to bind other proteins seems a crucial characteristic. To date more than 300binding partners have been identified, of which most are phosphoproteins. Consequently, it has become clear that 14-3-3proteins are involved in the regulation of most cellular processes, including several metabolic pathways, redox-regulation,transcription, RNA processing, protein synthesis, protein folding and degradation, cell cycle, cytoskeletal organization andcellular trafficking. In this review we include recent reports on the regulation of 14-3-3 by phosphorylation, and discussthe possible functional significance of the existence of distinct 14-3-3 isoforms in light of recent proteomics studies. Inaddition we discuss 14-3-3 interaction as a possible drug target.